Physicians frequently do not discuss the implications of driving with brain tumour patients or are not properly documenting such advice (or both). Clear and concise reporting guidelines need to be drafted given the legal, medical, and ethical concerns surrounding this public health issue.
INTRODUCTION
The onus for determining medical fitness to drive in patients with neurocognitive deficits falls primarily on the physician, although few have been formally trained in the area 1 . Most provinces and all 3 territories in Canada have a legal requirement for physicians to report drivers who they feel are medically unfit to drive 2 . Guidelines to report medically unfit drivers were drafted by the Canadian Medical Association and are clear for selected conditions such as seizures, which are immediate grounds for cessation of driving 3 . For less clear-cut cases, physicians are faced with a dilemma that juxtaposes the need to advocate both for patient autonomy and for public safety. There is a paucity of published data to inform evidence-based recommendations on when to intervene for these patients.
The incidence of brain tumours is rising in Canada, with an estimated 10,000 new diagnoses of primary and metastatic disease annually 4 . Brain tumours may result in visual changes, motor deficits, delayed reflexes, headaches, and seizures-all of which can impair a patient's ability to drive safely. Our group previously reported a pilot study evaluating the
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Methods
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Of the 158 patients available for analysis, 48 (30%) were reported to the mto, and 64 (41%) were advised to stop driving. With respect to the 53 patients with seizures, a report was submitted to the mto for 30 (57%), and a documented discussion about the implications of driving was held with 35 (66%). On univariate analysis, younger age, a central nervous system primary, higher brain radiotherapy dose, unifocal disease, and the presence of seizures were predictive of physician reporting (p < 0.05). On logistic regression modelling, the presence of seizures (odds ratio: 3.9) and a higher radiotherapy dose (odds ratio: 1.3) remained predictive of reporting.
influence of provincial legislation on the likelihood that Canadian radiation oncologists would report a brain tumour patient as medically unfit to drive to the provincial ministry of transportation 4 . Other Canadian studies have explored the appropriateness of physician reporting and vehicle operation by patients in other disease sites [5] [6] [7] [8] [9] [10] . Those studies collectively concluded that provincial laws are vague, physician responsibility is often unclear, and more tools are required to appropriately evaluate fitness to drive. However, like international studies, the foregoing studies were based solely on physician opinion rather than actual patterns of practice 11, 12 . Thus, we report here on our institutional experience of rates of physician discussion of fitness to drive, submission of a report to the Ontario Ministry of Transportation (mto), and time from either diagnosis or initial seizure to report submission in the context of brain tumours in a high-volume cancer centre in Southwestern Ontario.
METHODOLOGY
After obtaining institutional research ethics board approval, we used Cancer Care Ontario's Oncology Patient Information System to identify all patients diagnosed with primary or metastatic brain cancer and treated with brain radiotherapy between January and June 2009 at the London Regional Cancer Program. Records were cross-referenced with our institutional database to ensure accuracy of data. Three other regional cancer centres in Ontario were approached to participate in the study. All declined, with one centre citing legal concerns associated with the non-reporting of patients with seizures.
The records search at our institution identified 179 patients. Of those 179 patients, 21 were excluded from the analysis: 17 because they had received prophylactic cranial irradiation (12 for small-cell lung cancer, 5 for acute lymphoblastic leukemia), 2 because they were below the legal age to drive, and 2 because they died before discharge. Information pertaining to patient demographics (age, sex), diagnosis (date, site of origin, pathology), extent of disease (number of lesions), location of disease (anatomical lobe), presence of seizures, control of seizures (duration), previous treatment (surgery, chemotherapy, radiotherapy), potentially-unfit-to-drive report to the mto (date, by whom), and license reinstitution (date, by whom) were abstracted from the charts.
Descriptive statistics were calculated for baseline patient, tumour, and treatment characteristics. Bivariate analysis was also performed for the same characteristics stratified by sex, seizures (yes or no), and mto report (yes or no). Results of the bivariate analyses were compared using the chi-square test (or the Fisher exact test where appropriate) for categorical variables, and two-sample t-tests (or the Wilcoxon rank sum test, where appropriate) for continuous variables. Multivariate logistic regression modelling was performed to further determine factors associated with a mto report submission. Variables associated with a dependent variable (p < 0.15) were entered into the model and removed stepwise, using backward elimination procedures. Only variables showing a moderate level of association (p < 0.25) were retained in the final model. Time-to-event outcomes were estimated using the Kaplan-Meier method. All statistical analyses were two-sided and were performed using the SAS software application (version 9.2: SAS Institute, Cary, NC, U.S.A.) with p ≤ 0.05 indicative of statistical significance. Table i summarizes patient, tumour, and treatment characteristics, and factors predictive of a report being submitted to the mto. For the patient cohort, mean age was 62 years (range: 19-96 years), men predominated (58%), and the most common disease origins were metastasis from a lung primary (41%) and then a central nervous system primary (25%).
RESULTS
The overall rate of mto reporting was low. Reports were submitted for 48 patients (30%), most commonly by neurologists (60%) and oncologists (29%). A documented discussion about safe driving was held with 64 patients (41%). With respect to the 53 patients with seizures, a report was submitted to the mto for 30 (57%), and a documented discussion about the implications of driving was held with 35 (66%). A report was submitted to the mto for 4 patients (3%) without documentation in their medical record of a discussion on driving, and for 90 patients, the medical record documented neither a discussion nor a report submitted (57%).
On univariate analysis, younger age, central nervous system primary, higher brain radiotherapy dose, unifocal disease, and the presence of seizures were predictive of a report being submitted to the mto. On logistic regression analysis, the presence of seizures (odds ratio: 3.9) and a higher radiotherapy dose (odds ratio: 1.3) were the only predictive factors that remained statistically significant with respect to reporting ( Table ii) .
Of the 53 patients with seizures, 15 (28%) were diagnosed with a brain tumour after their first seizure, 17 (32%) were diagnosed on the same day as their first seizure, and 21 (40%) were diagnosed before a seizure occurred. Of the 48 patients reported, 44 (92%) were diagnosed before the report (range: 1 day-37.3 months), and 4 (8%) were diagnosed after the report (at 5, 56, 84, and 207 days later). For reported patients, the mean time from diagnosis (that is, imaging showing an intracranial mass) to report was 2.3 months (range: -6.8 to 37.3 months); however, excluding the 4 patients who were diagnosed after the report, the mean increased to 2.8 months (range: 0.03-37.3 months; Figure 1 mean time from first seizure to report was 23 days (range: 0-142 days; Figure 2 ).
INTERPRETATION
Each year, an estimated 5000 people in the United States are killed in motor vehicle accidents by medically unfit drivers 13 . The relative risk of a motor vehicle accident attributable to various medical conditions has been estimated to range from 2 to almost 8 times that attributable to healthy drivers 14 . However, for many patients, the ability to drive is an essential means to maintain autonomy in social, professional, and familial obligations. Physicians in Canada are thus faced with the difficult medical, ethical, and (often) legal responsibility to determine whether their patients are medically fit to drive a motor vehicle. The present study indicates that physicians frequently do not discuss the implications of driving or are not properly documenting such advice in medical records. We found that, although physicians were more commonly discussing the implications of driving for brain tumour patients with seizures, such patients were not routinely reported to the mto as unfit to drive despite clear guidelines related to this disorder. Even for the patients who were reported, the mean time from first seizure to report was just over 3 weeks, and in patients not having seizures, it was almost 3 months.
It is clear that neurocognitive sequelae from brain tumours may impair ability to drive, but practice patterns in assessing and reporting fitness to drive are highly variable. In an Australian survey, 73% of physicians were unaware of national reporting guidelines, and accordingly, nearly half the respondents had difficulty making a decision when asked by patients about driving ability 11 . An American survey similarly demonstrated that only 31% of respondents addressed driving restrictions with every patient having a brain tumour 12 . In a survey of Canadian radiation oncologists, our research group found that roughly three quarters of respondents consider reporting brain tumour patients to the mto, almost 90% feel that provincial laws are unclear about expectations, and nearly one quarter are unable to correctly identify their provincial legal requirement to report medically unfit drivers 4 . The only factor that significantly influenced inclination to report in 8 hypothetical brain tumour scenarios was the presence of provincial legislation in the respondent's jurisdiction of practice, suggesting that physicians may be practicing out of fear of litigation, rather than based on a medical assessment of risk.
The generalizability of our research might be challenged on the merits of it being performed retrospectively and within a single institution, but our findings do recapitulate previous survey studies that collectively concluded that physicians are uncertain in many cases about their duty in reporting medically unfit drivers. Another potential weakness of our study is that it examined only hospital records when, in fact, a driving assessment might have been performed or a report submitted by the family physician in the community. However, our research group previously conducted a multidisciplinary survey of specialists and family physicians caring for brain tumour patients and found that, compared with specialists, family doctors were even less comfortable with reporting, less likely to consider reporting, less likely to have patients inquire about driving, and less likely to engage in a discussion about safe driving 15 . Finally, given the retrospective nature of the present study, it was difficult to ascertain the driving status of patients at the time of disease presentation or whether other factors such as comorbidities or medication use deterred a physician from discussing driving ability or submitting a report. Nonetheless, Ontario has some of the strictest reporting laws in North America, with section 203(1) of the Highway Traffic Act stating that "physicians shall report every person greater than 16 years of age who is suffering from a condition that may make it dangerous for the person to operate a motor vehicle" 2 .
The utility of mandatory reporting laws for physicians caring for medically unfit drivers has been the subject of significant controversy, particularly for patients with seizure disorders 14 . A British study showed that only 72% of patients would inform their physician about breakthrough seizures in areas with mandatory reporting laws, compared with 96% of patients who would report breakthrough seizures if no mandatory reporting legislation was present 16 . Another British study similarly found that 75% of patients who experienced a seizure in the preceding year did not mention to their physician that they held a valid driving license 17 . Other confounding issues described in the literature include lengthy delays between reporting and license suspension 18 , difficulty and delays in attempting to reinstate licences 19 , and a sense of hostility or even a lack of compliance or hostility from patients after a report 20 .
To allow a broad range of people to drive, a certain degree of risk must be tolerated, and that toleration involves striking a balance between the need for people to be licensed to drive and the safety of the public on the roads. In 2003, a multidisciplinary working group was assembled by the Canadian Cardiovascular Society Consensus Conference for the Assessment of the Cardiac Patient for Fitness to Drive and Fly, and it determined that a 1 in 20,000 annual risk of death or serious injury to other road users was considered acceptable 21 . This consensus panel also described the use of a risk-of-harm formula derivation to assess driving fitness after implantation of a left ventricular assist device. In that case, the risk of harm to other road users posed by the driver was thought to be directly proportional to the time spent behind the wheel or the distance driven in a given time; the type of vehicle driven; the risk of sudden cardiac incapacitation; and the probability that such an event would result in a fatal or injury-producing accident 5 .
In the context of brain tumours, the United Kingdom recently created guidelines for driving restrictions designed according to perceived risk, based on histologic subtype and location of intracranial disease 22 . Similarly, the Cancer Institute of New South Wales Oncology Working Group for Neuro-Oncology assembled a multidisciplinary panel to create a brochure for clinicians that outlines a simple algorithm to provide informed advice and to guide decision-making on driving fitness 23 . A second pamphlet created by the same group is tailored for patients and their caregivers, outlining in lay terms why the patient should not be driving, what the responsibilities of the physician are, what the process is for returning to drive, and a list of alternatives to driving. At the present time, specific, clear, and concise guidelines for fitness to drive in brain tumour patients are lacking in Canada. Thus, we propose the formation of a multidisciplinary working group that would apply an evidence-based approach in devising Canadian standards to ensure that driving for patients with brain tumours is no longer a grey matter.
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